Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 53 in Threshold Pharmaceuticals

  1. Threshold Pharmaceuticals, Inc. Announces Initiation Of Dosing With...Read the original story

    Wednesday Jul 9 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.

    Comment?

  2. Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In...Read the original story

    Wednesday Jul 9 | Benzinga

    Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.

    Comment?

  3. Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean CapitalRead the original story

    Tuesday Jul 8 | AmericanBankingNews.com

    ... of 265.85% from the stock's previous close. Separately, analysts at Zacks upgraded shares of Threshold Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Shares of Threshold Pharmaceuticals ( ...

    Comment?

  4. Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung CancerRead the original story

    Monday Jul 7 | Seeking Alpha

    ... with the backing of a Merck KGaA partnership reiterates the potential of this undervalued company. Threshold Pharmaceuticals ( THLD ) is a development stage biopharmaceutical company currently evaluating its lead compound, TH-302, in several ...

    Comment?

  5. Threshold Pharmaceuticals, Inc. Initiates 440-Patient, Randomized,...Read the original story

    Tuesday Jul 1 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in advanced non-squamous non-small cell lung cancer .

    Comment?

  6. Threshold Pharmaceuticals Initiates 440-Patient, Randomized,...Read the original story

    Tuesday Jul 1 | Freshnews

    07/01/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in ...

    Comment?

  7. Biotech Future Looking RosyRead the original story w/Photo

    Sunday Jun 29 | Chemical & Engineering News

    ... approval. TH-302, a drug for soft-tissue sarcoma that Merck Serono developed in partnership with Threshold Pharmaceuticals, entered Phase III clinical trials last year. Second Genome , which focuses on microbiome proteomics, exemplified the firms at ...

    Comment?

  8. Threshold Pharmaceuticals, Inc. Announces Data From Ongoing Phase 1/2 ...Read the original story

    May 30, 2014 | BioSpace

    Objective response rate of 24% in patients with recurrent glioblastoma following progression on single-agent bevacizumab Median progression-free survival of 3.1 months on combination therapy vs. 2.4 months on prior single-agent bevacizumab Threshold Pharmaceuticals, Inc. today announced new clinical data from an ongoing investigator-sponsored Phase ... (more)

    Comment?

  9. Threshold Pharmaceuticals, Inc. Announces Data From Ongoing Phase 1/2 ...Read the original story

    May 30, 2014 | BioSpace

    Preliminary clinical benefit rate of 31% in patients treated at the maximum-tolerated dose of TH-302 and low-dose dexamethasone Objective responses observed in heavily pretreated patients including prior treatment with proteasome inhibitors [including carfilzomib ] and IMiDs [including pomalidomide ] Threshold Pharmaceuticals, Inc. today announced ... (more)

    Comment?

  10. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story

    May 30, 2014 | Market Wire

    ... . A replay of the presentation will be archived on the site for 30 days. About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low ...

    Comment?

  11. Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus...Read the original story

    May 30, 2014 | Sys-Con Media

    Preliminary clinical benefit rate of 31% in patients treated at the maximum-tolerated dose of TH-302 and low-dose dexamethasone Objective responses observed in heavily pretreated patients including prior treatment with proteasome inhibitors [including carfilzomib ] and IMiDs [including pomalidomide ] Threshold Pharmaceuticals, Inc. today announced ... (more)

    Comment?

  12. Threshold Pharmaceuticals, Inc. Announces Webcast of Analyst Event On Sunday, June 1, 2014Read the original story

    May 28, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the company will webcast its analyst event with clinical experts to be held on Sunday, June 1, 2014, from 6:00 PM to 7:30 PM Central Time at the Four Seasons Hotel Chicago.

    Comment?

  13. Threshold Announces Webcast of Analyst Event on Sunday, June 1, 2014Read the original story

    May 27, 2014 | Sys-Con Media

    Threshold Pharmaceuticals, Inc. today announced that the company will webcast its analyst event with clinical experts to be held on Sunday, June 1, 2014, from 6:00 PM to 7:30 PM Central Time at the Four Seasons Hotel Chicago.

    Comment?

  14. Threshold Pharmaceuticals Inc Files (8-K) Disclosing Change in...Read the original story

    May 21, 2014 | Hispanic Business

    THRESHOLD PHARMACEUTICALS INC FILES Disclosing Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits 2014 Equity Incentive Plan , which 2014 Plan became effective on that date.

    Comment?

  15. Market Report, "Myelofibrosis - Pipeline Review, H1 2014", PublishedRead the original story

    May 20, 2014 | SBWire

    ... Therapeutics, Inc., Celgene Corporation, Incyte Corporation, Geron Corporation, MEI Pharma, Inc., Threshold Pharmaceuticals, Inc., Acceleron Pharma, Inc., Promedior, Inc. About Fast Market Research Fast Market Research is a leading distributor of ...

    Comment?

  16. Relapsed Multiple Myeloma - Pipeline Review, H1 2014 - New Market ReportRead the original story

    May 16, 2014 | SBWire

    ... Biotech Inc., Pharmacyclics, Inc., Array BioPharma Inc., MorphoSys AG, Senesco Technologies, Inc., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Acceleron Pharma, Inc., Altor BioScience Corporation, Arno Therapeutics, Inc., Stemline ...

    Comment?

  17. New Market Research Report: Chronic Myelocytic Leukemia (CML, Chronic ...Read the original story

    May 15, 2014 | SBWire

    ... JW Pharmaceutical Corporation, Ilyang Pharmaceutical Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Natco Pharma Limited, SymBio Pharmaceuticals Limited, Nerviano Medical Sciences S.r.l., ...

    Comment?

  18. Metastatic Adenocarcinoma of the Pancreas - Pipeline Review, H1 2014Read the original story

    May 15, 2014 | SBWire

    ... BioTech, Inc. Halozyme Therapeutics, Inc. Oncolytics Biotech Inc. Peregrine Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. Axcentua Pharmaceuticals AB BioCancell Therapeutics, Inc. NewLink Genetics Corporation Eleison Pharmaceuticals, Inc. To ...

    Comment?

  19. Neuroendocrine Tumors - Pipeline Review, H1 2014Read the original story

    May 15, 2014 | SBWire

    ... Inc. Delcath Systems, Inc. Ipsen S.A. Novartis AG Progenics Pharmaceuticals, Inc. OXiGENE, Inc. Threshold Pharmaceuticals, Inc. Nobelpharma Co., Ltd. Gradalis Inc. Intezyne, Inc Chiasma, Inc. OctreoPharm Sciences GmbH DexTech Medical AB To view the ...

    Comment?

  20. Threshold Announces Clinical Data on TH-302 in Glioblastoma and...Read the original story

    May 14, 2014 | World News Report

    (Marketwired) -- 05/14/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from two ongoing Phase 1/2 clinical trials of its investigational hypoxia-activated prodrug, TH-302, will be presented during poster ...

    Comment?